(HealthDay)—One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative
Read moreHome »
New recommendations on genetic testing for prostate cancer
Prostate cancer is a leading cause of death from cancer in the US and especially in the Philadelphia region. Consistently,
Read more